25,100 Shares in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Acquired by Acuta Capital Partners LLC

Acuta Capital Partners LLC purchased a new stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) during the third quarter, according to the company in its most recent filing with the SEC. The firm purchased 25,100 shares of the biopharmaceutical company’s stock, valued at approximately $1,394,000. Ultragenyx Pharmaceutical comprises 1.1% of Acuta Capital Partners LLC’s investment portfolio, making the stock its 25th biggest position.

Several other institutional investors also recently made changes to their positions in the stock. Algert Global LLC raised its position in shares of Ultragenyx Pharmaceutical by 46.9% in the 3rd quarter. Algert Global LLC now owns 73,902 shares of the biopharmaceutical company’s stock worth $4,105,000 after buying an additional 23,580 shares during the period. Cerity Partners LLC acquired a new stake in Ultragenyx Pharmaceutical during the third quarter worth about $1,773,000. Charles Schwab Investment Management Inc. raised its holdings in shares of Ultragenyx Pharmaceutical by 10.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 594,521 shares of the biopharmaceutical company’s stock worth $33,026,000 after purchasing an additional 56,905 shares during the period. Massachusetts Financial Services Co. MA lifted its stake in shares of Ultragenyx Pharmaceutical by 46.5% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 542,373 shares of the biopharmaceutical company’s stock valued at $30,129,000 after purchasing an additional 172,126 shares in the last quarter. Finally, B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in shares of Ultragenyx Pharmaceutical during the 3rd quarter worth about $1,323,000. 97.67% of the stock is owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Price Performance

NASDAQ RARE opened at $48.13 on Thursday. The company’s fifty day moving average price is $52.48 and its two-hundred day moving average price is $48.57. The company has a market capitalization of $4.44 billion, a price-to-earnings ratio of -7.44 and a beta of 0.58. Ultragenyx Pharmaceutical Inc. has a 12 month low of $37.02 and a 12 month high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) EPS for the quarter, topping analysts’ consensus estimates of ($1.45) by $0.05. Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%. The business had revenue of $139.49 million during the quarter, compared to the consensus estimate of $135.28 million. During the same period last year, the firm earned ($2.23) earnings per share. The company’s revenue for the quarter was up 42.3% compared to the same quarter last year. As a group, analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -6.2 EPS for the current year.

Insider Activity

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 20,000 shares of the business’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $55.85, for a total transaction of $1,117,000.00. Following the completion of the sale, the chief executive officer now owns 2,223,985 shares in the company, valued at $124,209,562.25. The trade was a 0.89 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Howard Horn sold 7,465 shares of the stock in a transaction on Thursday, October 10th. The stock was sold at an average price of $52.76, for a total transaction of $393,853.40. Following the sale, the chief financial officer now directly owns 92,301 shares in the company, valued at $4,869,800.76. This trade represents a 7.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 27,556 shares of company stock worth $1,515,967. 5.80% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms recently commented on RARE. HC Wainwright raised their price target on shares of Ultragenyx Pharmaceutical from $82.00 to $95.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. Canaccord Genuity Group reissued a “buy” rating and issued a $121.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, November 12th. JPMorgan Chase & Co. decreased their price target on shares of Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating for the company in a research report on Thursday, November 21st. The Goldman Sachs Group raised their price objective on Ultragenyx Pharmaceutical from $67.00 to $76.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. Finally, Wedbush upped their target price on Ultragenyx Pharmaceutical from $43.00 to $46.00 and gave the stock a “neutral” rating in a research report on Friday, August 2nd. Two equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat, Ultragenyx Pharmaceutical presently has an average rating of “Moderate Buy” and a consensus target price of $87.46.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.